Ignite Creation Date:
2024-05-06 @ 6:25 PM
Last Modification Date:
2024-10-26 @ 2:47 PM
Study NCT ID:
NCT05653180
Status:
RECRUITING
Last Update Posted:
2023-04-03
First Post:
2022-12-06
Brief Title:
IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
Sponsor:
Innovent Biologics Suzhou Co Ltd
Organization:
Innovent Biologics Suzhou Co Ltd
Organization Data
Organization:
Innovent Biologics Suzhou Co Ltd
Class:
INDUSTRY
Study ID:
CIBI310J201
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Innovent Biologics Suzhou Co Ltd
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None